Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Los Angeles, California. www.InvestorBrandNetwork.com.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

AUGUST 24, 2021

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc.

Clinical Trials 105

Clinical Trials Treatment Pharmaceutical Concentrates 105

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

Clinical Trials 98

Clinical Trials Research and Development Hybrid Medicine 98

Cannabis Law Report

AUGUST 23, 2021

Phase I clinical trial of the Satipharm CBD capsules in which results demonstrated the safety and high performance of the oral capsule technology, including the superior delivery profile of cannabidiol (CBD) compound to trial subjects. The treatment was generally well tolerated and the median reduction in seizures was 81.9%

Clinical Trials 105

Clinical Trials CBD Epilepsy Treatment 105

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity. Silo Pharma Inc. Silo Pharma Inc.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Veriheal

AUGUST 22, 2022

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. Quite frankly, the clinical trials couldn’t have come at a better time. About the Opioid Epidemic. Together, they work very well. Synergistically, they co-work on some of the same receptors.”.

Clinical Trials 113

Clinical Trials Chronic Pain Hydroponic Strains 113

The Cannigma

OCTOBER 11, 2021

No clinical trial was used in the compilation of the study. The researchers themselves wrote that the study is the first “to document self-reported efficacy of CBG-predominant products,” and provides further indication that “CBG-predominant cannabis-based medicines should be studied in randomized controlled trials.”.

Conditions 132

Conditions Clinical Trials Chronic Pain Cannabinoids 132

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JULY 13, 2022

Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”. VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

TheAnswerPage

NOVEMBER 30, 2021

Psilocybin, the hallucinogen found in “magic mushrooms” has been used in clinical trials. According to the CSA, schedule I substances have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.

Clinical Trials 52

Clinical Trials Safety Treatment THC 52

TheAnswerPage

MARCH 29, 2022

Has the National Institute of Drug Abuse (NIDA) recently provided funding for a clinical trial evaluating the efficacy of a CBD product as an opioid-sparing agent for patients with radiculopathic pain? The primary efficacy outcome is a change in opioid maintenance dose from baseline to the end of the treatment period.

Clinical Trials 52

Clinical Trials Safety Medicine Treatment 52

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Canna Law Blog

NOVEMBER 15, 2021

There was a fascinating panel on the use of ketamine treatments for, among other things, depression and anxiety disorders. We continue to see an uptick in ketamine clinic transactions (the complexities of which we have written about extensively ). Pharmaceutical start-ups are betting on the treatment potential of psychedelics.

Clinical Trials 98

Clinical Trials Treatment Microdosing Pharmaceutical 98

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? Fletcher S. Child: care, health and development.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Canna Care Docs

OCTOBER 3, 2023

Conventional medication methods such as opiates may help terminal patients focus on more palliative treatment options and goals in order to better one’s comfort and overall quality of life during this time. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Neurological Disorders: Several cannabinoids show promise in the treatment of neurological disorders, including multiple sclerosis (MS) and Parkinson’s disease.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Medicinal Marijuana Association

FEBRUARY 11, 2024

The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community. Potential for enhanced treatment outcomes with cannabis use. Improves optic nerve blood flow and protects retinal cells.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. Still, research is ongoing.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

The Cannigma

MARCH 7, 2022

What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN. Those enrolled in the study will receive 28 days of treatment and then be assessed by pain-rating scales.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

MMJ Recs

DECEMBER 28, 2023

In recent years, a significant shift has occurred in the perception of medical marijuana, transforming it from a controversial substance to a recognized and, in some places, a legal form of medical treatment. Epidiolex, a CBD-based medication, has even received FDA approval for the treatment of specific seizure disorders.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

PrestoDoctor

OCTOBER 11, 2023

However, as part of a comprehensive treatment plan, CBD may offer a complementary approach to address some of the social symptoms associated with ASD. Another study involving human participants reported a significant reduction in anxiety and improvement in social communication skills after CBD treatment.

CBD 52

CBD Research and Development Clinical Trials Treatment 52

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JUNE 21, 2021

(OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. Press Release. Entheon Biomedical Corp. CSE: ENBI) announces agreement to acquire Lobo Genetics Inc. Press Release.

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JANUARY 31, 2022

The SAP is a federal program that allows healthcare professionals to apply for access to non-marketed medications that have not yet been approved for sale, when such medications show clinical evidence of safety and efficacy and are intended to treat patients with a severe or life-threatening illness.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. Most recently the FDA awarded MMJ International Holdings ?Orphan

DEA 66

DEA Clinical Trials THC Research and Development 66